Preclinical Research For Leukemia Announced By Innovative Therapeutics Company

Groundbreaking Preclinical Research by CERo Therapeutics Offers Hope for AML Patients.

Disclaimer: The information in this article is accurate as of its publication date.

In an unprecedented move in the fight against Acute Myeloid Leukemia (AML), CERo Therapeutics, Inc., an innovative biopharmaceutical company, has announced the publication of its preclinical research. The study supports the use of CER-1236, their clinical candidate, as a …